Grail Stock Jumps in August as FDA Schedules a Key Meeting for its Galleri Cancer Test
FDA approval for its multi-cancer early detection test, Galleri, would strengthen the case for the stock.
Grail, a multi-cancer early detection test company, experienced a significant 15.8% jump in its stock price during August, as reported by S&P Global Market Intelligence. However, the rise was not consistent throughout the month, with a decline in the initial half and a notable rebound in the latter part. This fluctuation was primarily driven by significant regulatory news.
Grail's primary objective is to persuade medical insurers of the cost-effectiveness and efficacy of its multi-cancer early detection (MCED) test, known as Galleri. The question at hand revolves around whether the test can detect cancer early enough to enhance patient outcomes and reduce costs associated with less invasive treatments.
This is a complex calculation, as insurers must take into account the expenses of confirmatory testing for patients who test positive for cancer through Galleri but are later found not to have cancer.
Despite these challenges, Grail's case was not bolstered by the failure to meet the primary endpoint of its extensive 3-year trial involving 142,000 participants across England's National Health Service. The trial aimed to demonstrate a statistically significant decrease in the incidence of late-stage (Stage III + IV) cancers across more than 50 different cancer types.
Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
